These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 15782510)
1. Engineering the economic value of two pediatric combination vaccines. Jacobson SH; Sewell EC; Karnani T Health Care Manag Sci; 2005 Feb; 8(1):29-40. PubMed ID: 15782510 [TBL] [Abstract][Full Text] [Related]
2. "Reverse engineering" a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccines. Sewell EC; Jacobson SH; Weniger BG Pediatr Infect Dis J; 2001 Nov; 20(11 Suppl):S45-56. PubMed ID: 11704724 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Avdicová M; Prikazský V; Hudecková H; Schuerman L; Willems P Eur J Pediatr; 2002 Nov; 161(11):581-7. PubMed ID: 12424582 [TBL] [Abstract][Full Text] [Related]
5. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640 [TBL] [Abstract][Full Text] [Related]
6. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Zepp F; Schuind A; Meyer C; Sänger R; Kaufhold A; Willems P Pediatrics; 2002 Apr; 109(4):e58. PubMed ID: 11927731 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine. Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Gabutti G; Zepp F; Schuerman L; Dentico P; Bamfi F; Soncini R; Habermehl P; Knuf M; Crovari P; Scand J Infect Dis; 2004; 36(8):585-92. PubMed ID: 15370670 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa. Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322 [TBL] [Abstract][Full Text] [Related]
10. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel). Johns TL; Hutter GE Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study. Monge S; Hahné SJ; de Melker HE; Sanders EA; van der Ende A; Knol MJ Lancet Infect Dis; 2018 Jul; 18(7):749-757. PubMed ID: 29752131 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Tichmann-Schumann I; Soemantri P; Behre U; Disselhoff J; Mahler H; Maechler G; Sänger R; Jacquet JM; Schuerman L Pediatr Infect Dis J; 2005 Jan; 24(1):70-7. PubMed ID: 15665713 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973 [TBL] [Abstract][Full Text] [Related]
14. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting. Lim FS; Phua KB; Lee BW; Quak SH; Teoh YL; Ramakrishnan G; Han HH; Van Der Meeren O; Jacquets JM; Bock HL Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):138-47. PubMed ID: 21323176 [TBL] [Abstract][Full Text] [Related]
15. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer. Dolhain J; Janssens W; Mesaros N; Hanssens L; Fierens F Expert Rev Vaccines; 2018 Jun; 17(6):513-524. PubMed ID: 29920121 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine. Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L; Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947 [TBL] [Abstract][Full Text] [Related]
17. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Bar-On ES; Goldberg E; Fraser A; Vidal L; Hellmann S; Leibovici L Cochrane Database Syst Rev; 2009 Jul; (3):CD005530. PubMed ID: 19588375 [TBL] [Abstract][Full Text] [Related]
18. Analyzing the economic value of the hepatitis B--Haemophilus influenzae type B combination vaccine by reverse engineering a formulary selection algorithm. Jacobson SH; Karnani T; Sewell EC Vaccine; 2003 May; 21(17-18):2169-77. PubMed ID: 12706708 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Yeh SH; Ward JI; Partridge S; Marcy SM; Lee H; Jing J; Curry ES; Howe BJ Pediatr Infect Dis J; 2001 Oct; 20(10):973-80. PubMed ID: 11642632 [TBL] [Abstract][Full Text] [Related]